Medicine and Dentistry
Randomized Controlled Trial
100%
Irritable Bowel Syndrome
93%
Cost-Effectiveness Analysis
76%
Cognitive Behavioral Therapy
70%
Treatment Resistant Depression
46%
Quetiapine
46%
Arm
44%
Health Care Cost
39%
Attention Deficit Disorder
23%
Immunoglobulin
23%
Transverse Myelitis
23%
Controlled Release
23%
Methylphenidate
23%
Social Adaptation
16%
Quality Adjusted Life Year
14%
Adverse Event
12%
Antidepressant
11%
General Medicine
8%
Gastroenterology
8%
Neuromyelitis Optica
7%
Diseases
7%
Clinician
7%
Quality of Life
6%
Add on Therapy
6%
Odds Ratio
6%
Methylprednisolone
5%
Antidepressant Medication
5%
Atypical Antipsychotic
5%
Symptomatology
5%
Major Depressive Episode
5%
Emotional Dysregulation
5%
Placebo
5%
Side Effect
5%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
93%
Osmotic Controlled-Release Oral Delivery System
46%
Methylphenidate
46%
Attention Deficit Disorder
46%
Treatment Resistant Depression
46%
Quetiapine
46%
Immunoglobulin
23%
Myelitis
23%
Antidepressant
17%
Placebo
14%
Myelooptic Neuropathy
7%
Diseases
7%
Add on Therapy
6%
DSM-5
6%
Spine Injury
5%
Methylprednisolone
5%
Adverse Event
5%
Major Depression
5%
Atypical Antipsychotics
5%
Symptomatology
5%
Side Effect
5%
Nursing and Health Professions
Irritable Colon
70%
Cost Effectiveness Analysis
55%
Cognitive Behavioral Therapy
46%
Quality Adjusted Life Year
32%
Self Care
26%
Confidence Interval
25%
Quetiapine
23%
Treatment Resistant Depression
23%
Odds Ratio
11%
General Practice
8%
Randomization
7%
Antidepressant
7%
Adverse Event
6%
Clinical Practice
5%
